Related Experiment Video

Updated: Aug 15, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

[Relationship between cyclooxygenase (COX)-2 and malignant tumors]

Rikio Yoshimura1, Masahide Matsuyama, Kenji Tsuchida

  • 1Department of Urology, Osaka City University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 13, 2005
PubMed

Insights

Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce cancer risk by inhibiting cyclooxygenase (COX) enzymes. This review explores COX-2 expression in urological cancers and the effects of COX inhibitors.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Context:

  • Epidemiologic studies and animal experiments suggest NSAIDs reduce colorectal carcinoma incidence.
  • Cyclooxygenase (COX) is the primary target of NSAIDs, inhibiting prostaglandin production from arachidonic acid.
  • COX enzymes may play a role in carcinogenesis initiation and promotion.

Purpose:

  • To review the expression of COX-2 in various urological cancer tissues.
  • To examine the effects of COX inhibitors on urological cancers.

Summary:

  • This review focuses on cyclooxygenase-2 (COX-2) expression in renal cell carcinoma, bladder tumors, prostate cancer, and testicular tumors.
  • It investigates the potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and their mechanism of action, COX inhibition, in the context of urological malignancies.
  • The role of prostaglandins (PGs) in carcinogenesis is also discussed.

Impact:

  • Highlights the potential therapeutic role of COX inhibitors in urological cancer treatment.
  • Provides insights into the molecular mechanisms underlying NSAID efficacy in cancer prevention and therapy.
  • Contributes to understanding the link between inflammation and cancer development in the urinary tract.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...